Skip to main content
TipRanks
Go Ultimate75% OFF

Evolent Health (EVH) Q3 2026 Earnings Report

754 Followers

EVH Q3 2026 EPS Results

Actual EPS
$0.06
Consensus EPS
$0.06
Beat/Miss
Missed by -$0.00
One Year Ago EPS
$0.05

EVH Q3 2026 Revenue Results

Actual Revenue
$725.37M
Expected Revenue
$727.06M
Beat/Miss
Missed by -$1.69M
YoY Revenue Growth
+51.27%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
Before Open
Conference Call
Thursday, November 5, 2026
EVH Upcoming Earnings

Evolent Health's next earnings date is estimated for February 24, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

EVH Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:-28.54%|
Earnings Call Sentiment|Positive

The call was strongly positive overall. Evolent reported sequential revenue, Adjusted EBITDA, and MER improvement; raised full-year Adjusted EBITDA guidance; highlighted significant customer renewals and expansions; and described substantial progress in oncology and AI. The primary challenges were lower Specialty Technology and Services revenue, known attrition, Medicaid-related membership headwinds, ongoing leverage and cash interest obligations, higher planned AI investment, and uncertainty around the precise pace of 2027 revenue growth.

Company Guidance

Management reiterated full-year 2026 revenue guidance of $2.6 billion-$2.7 billion, full-year MER of approximately 93%, and adjusted cost of revenue, excluding medical claims, but including medical device costs, plus adjusted SG&A of approximately $675 million for the year, while raising Adjusted EBITDA guidance to $130 million-$135 million, or $130 million to $135 million previously $120 million to $135 million; fourth-quarter Adjusted EBITDA is expected to increase approximately $11 million-$16 million sequentially, and cash flow from operations is expected to be $10 million to $20 million after approximately $60 million of annual cash interest expense, with capital expenditures of $26 million-$28 million for the year and up to $50 million deployed toward reducing outstanding indebtedness by the end of the year. For 2027, management expects strong growth led by Performance Suite, the midpoint of 2027 Adjusted EBITDA guidance will be $150 million or higher, AI-related capital expenditures to be higher in 2027 than in 2026, initiatives to begin generating returns in late 2027, and more than 80% of all manual auths, or approximately 2 million cases, to run through AuthIntelligence by the end of 2027; detailed 2027 guidance, including a specific revenue range, will be provided with fourth-quarter results in February.

  • Strong Third-Quarter Revenue and Adjusted EBITDA GrowthTotal revenue was $725 million, up approximately 11% versus Q2. Adjusted EBITDA was $34.3 million, up approximately 22% sequentially and slightly above the midpoint of the previously outlined $4 million to $7 million increase.
  • Improved Medical Expense RatioThe medical expense ratio was 93% in Q3 versus 95% in Q2, an approximately 220 basis point sequential improvement, due to favorable in-year claims development that came through earlier than expected and contractual adjustments.
  • Raised Full-Year Adjusted EBITDA GuidanceEvolent reiterated full-year revenue guidance of $2.6 billion-$2.7 billion and raised Adjusted EBITDA guidance to $130 million to $135 million from $120 million to $135 million previously.
  • Performance Suite Revenue GrowthPerformance Suite revenue was $564 million, up approximately 16% quarter-over-quarter, primarily due to a full quarter of Highmark revenue and the recognition of contractual adjustments.
  • Multi-Year Surgical Management RenewalThe company renewed its largest Surgical Management customer contract for an additional four years, which management described as evidence of the customer's continued commitment to Evolent's musculoskeletal and cardiovascular care model.
  • Oncology Expansion Across Additional States and LivesAn existing client agreed to expand its oncology offering into several additional states, covering approximately 1 million commercial lives, with go-live expected January 1, 2027. The expansion also includes Member Navigation across both existing and new lives.
  • National Payer Specialty Technology and Services ExpansionEvolent is adding 11 states to an existing national payer relationship effective November 1, 2026, expanding the footprint from 39 states to 50 states. The client now represents approximately 7 million lives managed by Evolent.
  • New Cancer Care Model with American Oncology NetworkEvolent rolled out a new cancer care model with the American Oncology Network across clinics in eight states. The model is designed to reduce the prior authorization burden for providers and improve quality, timeliness, and affordability for patients.
  • Positive Highmark Implementation ProgressManagement said Highmark, which launched in May, is progressing ahead of plan, with all leading indicators tracking better than budget.
  • Oncology Remains the Primary Growth DriverManagement expects oncology to represent over 70% of Evolent's 2027 revenue. The company is expanding oncology Member Navigation and embedding clinical pathways directly into the electronic medical records of leading oncology groups, with both innovations expected to continue expanding over the coming years.
  • AuthIntelligence Scaling Beyond Pilot PhaseAuthIntelligence, Evolent's AI utilization-management platform, is deployed across products representing approximately 6 million of Evolent's roughly 9 million annual reviews. Where deployed, it evaluates approximately half of prior authorization volume that previously required manual clinical review and currently touches approximately 1 million cases per year.
  • Improved Auto-Authorization RatesAt customers and case types where AuthIntelligence is deployed, auto-approval rates have improved by as much as 20 percentage points, including instances where auto-authorization increased from 60% to 80%. A 10% improvement in the auto-authorization rate translates to approximately 600,000 fewer manual touches per year.
  • Planned Expansion of AI CoverageEvolent expects more than 80% of all manual authorizations, or approximately 2 million cases, to run through AuthIntelligence by the end of 2027. Management expects AI-related efficiencies to be part of the 2027 outlook, with returns beginning in late 2027 primarily through cost reductions and additional returns in 2028 and beyond from lower operating costs and new product launches.
  • Operating Expense Discipline and Efficiency EffortsStaffing costs were relatively flat compared with Q2 2026 in both adjusted cost of revenue and adjusted SG&A, reflecting ongoing operating efficiencies. The company continues to pursue cost improvements while funding technology investments needed to support the business.
  • Higher Fourth-Quarter EBITDA OutlookEvolent now expects a fourth-quarter sequential Adjusted EBITDA increase of approximately $11 million-$16 million, above the previously outlined $7 million-$15 million step-up, due to continued MER upside.
  • 2027 EBITDA ConfidenceManagement maintained confidence that the midpoint of 2027 Adjusted EBITDA guidance will be $150 million or higher, supported by improved MER performance and AI-related cost reductions in the second half of 2027.
  • Balance Sheet Deleveraging PlanEvolent is targeting deployment of up to $50 million toward reducing outstanding indebtedness by the end of the year. Management said the plan reflects confidence in the business, the earnings trajectory, customer renewals, Performance Suite partnerships, and expected cash generation as those partnerships mature.
  • Election-Related Potential Upside Not Included in OutlookManagement said the $150 million 2027 EBITDA assumption includes no change to the One Big Beautiful Bill and no impact from the election. A rollback or change to Medicaid work requirements or exchange subsidies was described as having a significant positive impact, but none of that potential upside is included in the current outlook.

EVH Earnings History

EVH earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 24, 20272026 (Q4)0.16-0.08――
Nov 05, 20262026 (Q3)0.060.060.0520.00% (+0.01)
Aug 06, 20262026 (Q2)-0.010.02-0.1120.00% (+0.12)
May 07, 20262026 (Q1)-0.05-0.020.06-133.33% (-0.08)
Feb 24, 20262025 (Q4)0.050.08-0.02500.00% (+0.10)
Nov 06, 20252025 (Q3)0.100.050.0425.00% (+0.01)
Aug 07, 20252025 (Q2)0.07-0.100.3-133.33% (-0.40)
May 08, 20252025 (Q1)0.090.060.34-82.35% (-0.28)
Feb 20, 20252024 (Q4)0.03-0.020.23-108.70% (-0.25)
Nov 07, 20242024 (Q3)0.310.040.3-86.67% (-0.26)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed